Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Expandable Stent Graft Treats Peripheral Artery Disease

By HospiMedica International staff writers
Posted on 14 Feb 2017
A novel balloon expandable stent graft aids treatment of de novo or restenotic lesions found in the iliac arteries, including lesions at the bifurcation.

The Viabahn VBX balloon expandable endoprosthesis consists of a 316L surgical grade stainless steel balloon expandable stent and a fluoropolymer graft with a proprietary heparin surface of porcine origin. More...
The VBX is available in diameters ranging from 5 to 11 millimeters and lengths of 15, 19, 29, 39, 59, and 79 millimeters, as well as two shaft lengths, thus covering a wide variety of treatment needs up to 110 mm. In addition, it does not require pre-dilation, thus reducing the number of balloons required, contributing to procedural cost savings.

The VBX endoprosthesis is pre-mounted on a delivery system compatible with 0.035" guidewires, and is equipped with two radiopaque balloon markers embedded in the shaft to aid in correct placement. The delivery system can also be used for initial stent placement and post stent dilatation. The Viabahn VBX balloon expandable endoprosthesis is a product of Gore Medical Products, and has been approved by the U.S. Food and Drug Administration (FDA).

“The VBX Stent Graft combines radial strength with trackability and implanted conformability that results in successful outcomes for patients, providers, and physicians,” said Ray Swinney, peripheral interventional business leader at Gore. “There were no reported incidences of device dislodgement, failures in stent integrity, or device-related serious adverse events through the primary endpoint follow up, meaning no additional costs incurred for either endovascular or surgical stent removal.”

“The VBX Stent Graft demonstrated notable immediate and nine-month safety and efficacy in treating patients with iliac occlusive disease, which can be attributed to the exceptional device design,” said Jean Bismuth, MD, of Houston Methodist Hospital, who led the clinical study of the device. “Overall, there were multiple clinical benefits observed, including no median change in the device length upon deployment and a 100% technical success rate, with no occurrences of stent dislodgement or significant residual stenosis.”

PAD is a narrowing of the peripheral arteries due to atherosclerosis, and is most common in the arteries of the pelvis and legs. The most common symptoms of PAD are cramping, pain, or tiredness in the leg or hip muscles while walking or climbing stairs, which is temporarily relieved by rest. PAD sufferers have four to five times more risk of heart attack or stroke, and if left untreated, it can lead to gangrene and amputation.


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Emergency Ventilator
Shangrila935
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.